Teva lands Allergan generics business for $40.5B, drops hostile Mylan bid
Jul 27, 2015 - The Deal Pipeline
Mergers and Acquisitions
Following months of chasing generics giant Mylan NV (MYL), Teva Pharmaceutical Industries Ltd. (TEVA) announced on Monday that it would acquire the generics business of Allergan plc (AGN) for $40.5 billion.
The deal will mean that Allergan will receive $33.75 billion in cash and shares of Jerusalem-based Teva, valued at $6.75 billion. The purchase of Allergan Generics represents a 10% ownership in Teva for Allergan.Â
Teva estimated that Allergan's generics business will provide $2...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
